Dashboard
Manage Tickers

VIRVir Biotechnology, Inc.

Nasdaq vir.bio


$ 7.84 $ 0.06 (0.77 %)    

Monday, 09-Sep-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 7.82
$ 7.82 x 100
$ 7.83 x 200
-- - --
$ 7.41 - $ 13.09
1,106,516
na
1.07B
$ -0.83
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2024 06-30-2024 10-Q
2 05-03-2024 03-31-2024 10-Q
3 02-26-2024 12-31-2023 10-K
4 11-03-2023 09-30-2023 10-Q
5 08-04-2023 06-30-2023 10-Q
6 05-08-2023 03-31-2023 10-Q
7 02-28-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 02-28-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 02-25-2021 12-31-2020 10-K
16 11-10-2020 09-30-2020 10-Q
17 08-11-2020 06-30-2020 10-Q
18 05-12-2020 03-31-2020 10-Q
19 03-26-2020 12-31-2019 10-K
20 11-19-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Vir Biotechnology Announces Closing Of Exc...
09/09/2024 20:16:37

– License of proprietary masking platform further strengthens Vir's drug discovery capabilities in oncology and infectious ...

hc-wainwright--co-reiterates-buy-on-vir-biotechnology-maintains-110-price-target
HC Wainwright & Co. Reiterates Buy on Vir ...
08/20/2024 10:19:22

HC Wainwright & Co. analyst Patrick Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $110 pri...

breaking-down-vir-biotechnology-6-analysts-share-their-views
Breaking Down Vir Biotechnology: 6 Analyst...
08/02/2024 15:01:06

barclays-maintains-overweight-on-vir-biotechnology-raises-price-target-to-28
Barclays Maintains Overweight on Vir Biote...
08/02/2024 14:11:19

Barclays analyst Gena Wang maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and raises the price target from $27 t...

trading-halt-halt-status-updated-at-42500-pm-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 4:25:...
08/01/2024 20:25:06

vir-biotechnology-lowers-fy-2024-operating-expense-guidance-to-580-610m-due-to-workforce-restructuring-and-phasing-out-influenza-covid-19-and-t-cell-based-viral-vector-programs-includes-90---80m-in-stock-based-compensation-and-40---30m-in-restructuring-charges-excludes-sanofi-transaction-impact-to-be-updated-in-q3-2024-earnings-approximately-3-of-gaap-operating-expense-funded-by-grants
Vir Biotechnology Lowers FY 2024 Operating...
08/01/2024 20:22:56

vir-biotechnology-q2-2024-adj-eps-102-misses-090-estimate-sales-310m-miss-750m-estimate
Vir Biotechnology Q2 2024 Adj EPS $(1.02) ...
08/01/2024 20:21:49

Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(1.02) per share which missed the analyst consensus estimate of $(...

Core News & Articles
Vir Biotechnology Enters Exclusive Worldwi...
08/01/2024 20:07:19

trading-halt-halted-at-40010-pm-et---trading-halt-halt-news-pending
Trading Halt: Halted at 4:00:10 p.m. ET - ...
08/01/2024 20:00:13

vir-biotechnologys-hepatitis-delta-drug-combo-receives-fda-clearance-and-fast-track-status
Vir Biotechnology's Hepatitis Delta Drug C...
06/26/2024 12:06:40

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the U.S. Food and Drug Administration (FDA) has cleared its investiga...

morgan-stanley-maintains-equal-weight-on-vir-biotechnology-raises-price-target-to-15
Morgan Stanley Maintains Equal-Weight on V...
06/06/2024 13:12:28

Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Equal-Weight and raises the price tar...

why-is-infectious-disease-focused-vir-biotechnology-stock-trading-higher-on-wednesday
Why Is Infectious Disease-Focused Vir Biot...
06/05/2024 18:51:30

Vir Biotechnology reports promising Phase 2 SOLSTICE hepatitis delta trial results, showing high virologic response and ALT nor...

why-lands-end-shares-are-trading-lower-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why Lands' End Shares Are Trading Lower? H...
06/05/2024 17:04:26

hc-wainwright--co-reiterates-buy-on-vir-biotechnology-maintains-110-price-target
HC Wainwright & Co. Reiterates Buy on Vir ...
06/05/2024 16:20:42

HC Wainwright & Co. analyst Patrick Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $110 pri...

needham-maintains-buy-on-vir-biotechnology-raises-price-target-to-19
Needham Maintains Buy on Vir Biotechnology...
06/05/2024 16:19:01

Needham analyst Joseph Stringer maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $15 to ...

ollies-bargain-outlet-posts-upbeat-earnings-joins-verint-systems-guidewire-software-and-other-big-stocks-moving-higher-on-wednesday
Ollie's Bargain Outlet Posts Upbeat Earnin...
06/05/2024 14:23:46

vir-biotechnology-announced-new-preliminary-data-from-phase-2-solstice-hepatitis-delta-trial-showing-tobevibart-alone-or-combined-with-elebsiran-was-generally-well-tolerated-and-patients-achieved-high-virologic-response-and-alt-normalization
Vir Biotechnology Announced New Preliminar...
06/05/2024 09:36:18

evaluating-vir-biotechnology-insights-from-5-financial-analysts
Evaluating Vir Biotechnology: Insights Fro...
05/24/2024 17:01:04

hc-wainwright--co-reiterates-buy-on-vir-biotechnology-maintains-110-price-target
HC Wainwright & Co. Reiterates Buy on Vir ...
05/24/2024 16:48:41

HC Wainwright & Co. analyst Patrick Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $110 pri...

vir-biotechnologys-solstice-data-to-be-featured-at-the-european-association-for-the-study-of-the-liver-congress-2024
Vir Biotechnology's SOLSTICE Data To Be Fe...
05/21/2024 12:30:20

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the EASL Congress has changed the Company's Phase 2 SOLSTICE hepatitis...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION